Tumor Plasticity and Resistance to Immunotherapy

Area of Science:

• Oncology
• Cancer Biology
• Immunotherapy

Background:

• Tumor cell plasticity, characterized by epithelial-mesenchymal transition (EMT), is a key mechanism enabling cancer cells to acquire migratory and invasive properties.
• EMT-induced dedifferentiation confers resistance to conventional and targeted cancer therapies, posing a significant clinical challenge.
• Understanding the interplay between tumor plasticity and treatment response is crucial for developing more effective cancer interventions.

Purpose of the Study:

• To review current research on the role of tumor plasticity in mediating resistance to cancer immunotherapies.
• To discuss the implications of epithelial-mesenchymal transition (EMT) in the context of immunotherapy resistance.
• To explore potential combination immunotherapy strategies aimed at overcoming plasticity-driven resistance.

Main Methods:

• Literature review of current research findings.
• Analysis of studies investigating tumor plasticity and immunotherapy response.
• Synthesis of information on combination therapy approaches.

Main Results:

• Tumor cell plasticity, including EMT, is increasingly recognized as a mechanism of resistance to various immunotherapy modalities.
• The dedifferentiated, mesenchymal phenotype associated with EMT can alter tumor immunogenicity and the tumor microenvironment, impacting immune cell infiltration and function.
• Evidence suggests that targeting EMT or combining therapies may enhance anti-tumor immune responses.

Conclusions:

• Tumor plasticity represents a significant hurdle for effective cancer immunotherapy.
• Combination immunotherapy strategies that address or overcome tumor cell plasticity are essential for improving treatment outcomes.
• Further research into targeting EMT and its downstream effects is warranted to enhance immunotherapy efficacy in resistant cancers.